| Literature DB >> 28063071 |
Roberto Giacomelli1, Vasiliki Liakouli2, Onorina Berardicurti2, Piero Ruscitti2, Paola Di Benedetto2, Francesco Carubbi2, Giuliana Guggino3, Salvatore Di Bartolomeo2, Francesco Ciccia3, Giovanni Triolo3, Paola Cipriani2.
Abstract
Systemic sclerosis (SSc) has the highest fatality rate among connective tissue diseases and is characterized by vascular damage, inflammation and fibrosis of the skin and various internal organs. Interstitial lung disease (ILD) frequently complicates SSc and can be a debilitating disorder with a poor prognosis. ILD is the most frequent cause of death in SSc, and the management of SSc-ILD patients is a great challenge. Early detection of pulmonary involvement based on a recent decline of lung function tests and on the extent of lung involvement at high-resolution computed tomography is critical for the best management of these patients. This article summarizes classification, pathogenesis, diagnosis, prognosis, survival and finally current and future treatment options in SSc-ILD.Entities:
Keywords: Fibrosis; Interstitial lung disease; Scleroderma; Systemic sclerosis; Treatment
Mesh:
Substances:
Year: 2017 PMID: 28063071 DOI: 10.1007/s00296-016-3636-7
Source DB: PubMed Journal: Rheumatol Int ISSN: 0172-8172 Impact factor: 2.631